The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease
Open accessAbstract
Parkinson's disease (PD) is a common neurodegenerative disease affecting up to one million individuals in the United States. Depression is found in 40 to 50% of these patients and is associated with a variety of poor outcomes for both patients and their families. Despite this, there are few evidence‐based data to guide clinical care. This was an NIH‐funded, randomized, controlled trial of paroxetine, nortriptyline, and placebo. It included an 8 week acute phase and a 16 week blind extension phase. This report details the impact of depression treatment on quality of life (QoL) and disability in the acute and extension phase of this study. Secondary outcomes included relapse, tolerability, safety, and the impact of depression treatment on PD physical functioning. Patients who had improvement in depression, compared with those who did not, had significant gains in measures of QoL and disability (PDQ‐8, P = 0.0001; SF‐36, P = 0.0001) at 8 weeks and maintained their gains in the extension phase. Patients who were on active drug were significantly less likely to relapse in the extension phase than those on placebo (P = 0.041). Though relatively modest in size, this trial provides the first controlled data on the impact of treatment of depression on QoL and disability in PD. It suggests that successfully treating depression in PD leads to important, sustained improvements in these outcomes and that patients who improve on antidepressants are less likely to relapse than are patients who initially improve on placebo. © 2009 Movement Disorder Society
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
High psychological distress is associated with increased disability, progression rate of physical symptoms, incidence of relapse, healthcare costs, caregiver distress, and poor treatment compliance in PD.
“High psychological distress is also associated with increased disability, progression rate of physical symptoms, incidence of relapse, healthcare costs, and caregiver distress, as well as poor treatment compliance [11–13].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · see citing works
(1976) · Medical Entomology and Zoology · Cited by 8,899 · see citing works
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110 · see citing works
Linear Mixed Models for Longitudinal Data
Molenberghs, G., & Verbeke, G. N. (2000) · Springer series in statistics · doi:10.1007/978-1-4419-0300-6 · Cited by 2,681 · see citing works
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163 · see citing works
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 2× · see citing works
“We believe that the CGI-C score, which is relevant to the overall estimate of the patients condition and has been widely used as an estimate of relapse, is the best available approach for a clinical study such as this and is consistent with the definition proposed by Frank et al.(21) Study group (nortriptyline, paroxe…”
MethodRecent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,926 · see citing works
Short form 36 (SF36) health survey questionnaire: normative data for adults of working age.
Jenkinson, C., Coulter, A., & Wright, L. (1993) · BMJ · doi:10.1136/bmj.306.6890.1437 · Cited by 1,714 · see citing works
A systematic review of prevalence studies of dementia in Parkinson's disease
Aarsland, D., ZACCAI, J. H., & Brayne, C. (2005) · Movement Disorders · doi:10.1002/mds.20527 · Cited by 1,689 · see citing works
What contributes to quality of life in patients with Parkinson's disease?
Schrag, A. E. (2000) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.69.3.308 · Cited by 1,380 · see citing works
A systematic review of prevalence studies of depression in Parkinson's disease
Reijnders, J. S. A. M., Ehrt, U., Weber, W. E. J., Aarsland, D., & Leentjens, A. F. G. (2008) · Movement Disorders · doi:10.1002/mds.21803 · Cited by 1,239 · see citing works
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 1× · see citing works
“However, in a systematic review of the literature on depression relapse in nonPD patients, the average rate of relapse was 41% in people receiving placebo compared with 18% for those continuing antidepressant treatment.(27) Thus, our results are comparable to those observed in the nonPD population and suggest that ant…”
ResultNon-recognition of depression and other non-motor symptoms in Parkinson's disease
Shulman, L. M., Taback, R. L., Rabinstein, A. A., & Weiner, W. J. (2002) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(01)00015-3 · Cited by 695 · see citing works
Schrag, A. E., Hovris, A., Morley, D., Quinn, N. P., & Jahanshahi, M. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.06.011 · Cited by 551 · see citing works
Factors impacting on quality of life in Parkinson's disease: Results from an international survey
The Global Parkinson's Disease Survey (GPDS) Steering Committee (2002) · Movement Disorders · doi:10.1002/mds.10010 · Cited by 521 · see citing works
Depression in Parkinson??s Disease
STARKSTEIN, S. E., Preziosi, T. J., BOLDUC, P. L., & ROBINSON, R. G. (1990) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199001000-00005 · Cited by 482 · see citing works
The PDQ-8: Development and validation of a short-form parkinson's disease questionnaire
Jenkinson, C., Fitzpatrick, R. M., Peto, V., Greenhall, R., & Hyman, N. M. (1997) · Psychology and Health · doi:10.1080/08870449708406741 · Cited by 462 · see citing works
A controlled trial of antidepressants in patients with Parkinson disease and depression
Menza, M. A., Dobkin, R. D., Marín, H., Mark, M. H., Gara, M. A., Buyske, S. G., Bienfait, K., & Dicke, A. (2008) · Neurology · doi:10.1212/01.wnl.0000336340.89821.b3 · Cited by 413 · see citing works
Self-citationQuality of life and depression in Parkinson's disease
Schrag, A. E. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.05.030 · Cited by 380 · see citing works
Determinants of disability and quality of life in mild to moderate Parkinson disease
Muslimović, D., Post, B., Speelman, J. D., Schmand, B. A., & de Haan, R. J. (2008) · Neurology · doi:10.1212/01.wnl.0000313835.33830.80 · Cited by 351 · see citing works
Quality of life assessments in major depressive disorder: a review of the literature
Papakostas, G. I., Petersen, T., Mahal, Y., Mischoulon, D., Nierenberg, A. A., & Fava, M. (2004) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2003.07.004 · Cited by 331 · see citing works
The impact of depressive symptoms in early Parkinson disease
Ravina, B. M., Camicioli, R. M., Como, P. G., Marsh, L., Jankovic, J. J., Weintraub, D. A., & Elm, J. J. (2007) · Neurology · doi:10.1212/01.wnl.0000268695.63392.10 · Cited by 301 · see citing works
Research diagnostic criteria for Parkinson's disease.
Ward, C. D., & Gibb, W. R. G. (1990) · PubMed · Cited by 265 · see citing works
The Burden of Parkinson's Disease on Society, Family, and the Individual
Whetten‐Goldstein, K., Sloan, F. A., Kulas, E., Cutson, T. M., & Schenkman, M. L. (1997) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1997.tb01512.x · Cited by 229 · see citing works
Recognition and Treatment of Depression in Parkinson's Disease
Weintraub, D. A., Moberg, P. J., Duda, J. E., Katz, I. R., & Stern, M. B. (2003) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988703256053 · Cited by 209 · see citing works
Antidepressant studies in Parkinson's disease: A review and meta‐analysis
Weintraub, D., Morales, K. H., Moberg, P. J., Bilker, W. B., Balderston, C., Duda, J. E., Katz, I. R., & Stern, M. B. (2005) · Movement Disorders · doi:10.1002/mds.20555 · Cited by 191 · see citing works
McKinlay, A., Grace, R. C., Dalrymple‐Alford, J. C., Anderson, T., Fink, J., & Roger, D. (2007) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.05.009 · Cited by 164 · see citing works
Jenkinson, C., & Fitzpatrick, R. M. (2006) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2006.06.006 · Cited by 123 · see citing works
Antonini, A., Tesei, S., Zecchinelli, A., Barone, P., Gaspari, D. D., Canesi, M., Sacilotto, G., Meucci, N., Mariani, C. B., & Pezzoli, G. (2006) · Movement Disorders · doi:10.1002/mds.20895 · Cited by 118 · see citing works
Psychiatric issues in Parkinson's disease. A practical guide
Schrag, A. E. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.081927 · Cited by 12 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [12]First MB Spritzer RL Gibbon M Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition 1995 New York, NY Biometrics Research Department, New York State Psychiatric Institute
Cited by
Sorted by citations
Barone, P., Poewe, W., Albrecht, S., Debieuvre, C., Massey, D., Rascol, O., Tolosa, E., & Weintraub, D. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70106-x · Cited by 562 · see citing works
Czarny, P., Wigner, P., Galecki, P., & Sliwinski, T. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.06.036 · Cited by 310 · see citing works
Kwok, J. Y. Y., Kwan, J. C. Y., Auyeung, M., Mok, V. C. T., & Chan, H. Y. L. (2017) · Trials · doi:10.1186/s13063-017-2223-x · Cited by 56 · see citing works
Rodgers, S. H., Schütze, R., Gasson, N., Anderson, R. A., Kane, R. T., Starkstein, S., Morgan-Lowes, K., & Egan, S. J. (2019) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s135246581800070x · Cited by 43 · see citing works
- Authors
- Menza, M., Dobkin, R. D., Marin, H., Mark, M. H., Gara, M., Buyske, S., Bienfait, K., & Dicke, A.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- Corresponding author
- Menza, Matthew
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2009-05
- Volume
- 24
- Issue
- 9
- Pages
- 1325-1332
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- PMC
- PMC2819360
- OpenAlex
- W1975831734
- Cited by
- 106
- References
- 30
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 5 · 2020: 5 · 2019: 6 · 2018: 5 · 2017: 7 · 2016: 5 · 2015: 7 · 2014: 3 · 2013: 13 · 2012: 7
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Movement Disorders (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Rutgers University Community Repository (Rutgers University) (submittedVersion)
- Funders
- National Institute of Neurologic Disorders and Stroke (RO1NS043144)
- GlaxoSmithKline
- Clinical Trials Registration: Clintrials.gov Identifier (NCT 00062738)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Neurology › Neurological disorders and treatments
- Keywords
- Parkinson's disease, depression, antidepressant treatment, paroxetine, nortriptyline, quality of life, disability, relapse, physical function, PDQ-8, SF-36
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antidepressive Agents, Depression, Disability Evaluation, Double-Blind Method, Female, Humans, Male, Middle Aged, Nortriptyline, Parkinson Disease, Psychiatric Status Rating Scales, Quality of Life, Recurrence, Treatment Outcome, Paroxetine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
